Tetra Radar · FDA Approvals · Decision date
ecopipam: FDA decision date
Royalty Pharma plc (RPRX) · First quarter of 2027
In August 2026, Teva announced that the FDA accepted its NDA for ecopipam for the treatment of pediatric Tourette syndrome and granted the application Priority Review with a PDUFA date late in the first quarter of 2027.
Source: 10-Q of 4 November 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.